ࡱ> yx ZO`\pMicrosoft Office-gebruiker [Ba==i78X@"1Calibri1Calibri1Calibri1Calibri1Calibri1*h6 Calibri Light1,6Calibri16Calibri16Calibri1Calibri1Calibri1<Calibri1>Calibri1?Calibri14Calibri14Calibri1 Calibri1 Calibri1Calibri1Calibri1 Calibri1Calibri1.Source Sans Pro;" "\ #,##0_);\(" "\ #,##0\)E " "\ #,##0_);[Red]\(" "\ #,##0\)G!" "\ #,##0.00_);\(" "\ #,##0.00\)Q&" "\ #,##0.00_);[Red]\(" "\ #,##0.00\)u*8_(" "\ * #,##0_);_(" "\ * \(#,##0\);_(" "\ * "-"_);_(@_).))_(* #,##0_);_(* \(#,##0\);_(* "-"_);_(@_),@_(" "\ * #,##0.00_);_(" "\ * \(#,##0.00\);_(" "\ * "-"??_);_(@_)6+1_(* #,##0.00_);_(* \(#,##0.00\);_(* "-"??_);_(@_)                                                                     ff  `@ @      + )  P@ @  P@ @  @              a@ >   , *   (      ||Bqp'}-} 00\);_(*}-} 00\);_(*}-} 00\);_(*}-} 00\);_(*}-} 00\);_(*}-} 00\);_(*}-} 00\);_(*}-} 00\);_(*}-} 00\);_(*}-}  00\);_(*}-}  00\);_(*}-}  00\);_(*}-}  00\);_(*}-}  00\);_(*}-} 00\);_(*}-} 00\);_(*}-}7 00\);_(*}A}/ 00\);_(* * \}A}0 00\);_(*? * \}A}1 00\);_(*23 * \}-}2 00\);_(*}A}+ a00\);_(* * \}A}5 00\);_(* * \}A}3 W00\);_(* * \}}, ??v00\);_(*̙ * \.00\"\ * _);_ }}9 ???00\);_(* * \???.00\???"\ * ???_);_ ???}}( }00\);_(* * \.00\"\ * _);_ }A}* }00\);_(* * \}}) 00\);_(* * \???.00\???"\ * ???_);_ ???}-}= 00\);_(*}}4 00\);_(* * \.00\"\ * _);_ }-}< 00\);_(*}U}8 00\);_(* * \.00\}A}" 00\);_(* * \}A} 00\);_(*ef * \}A} 00\);_(*L * \}A} 00\);_(*23 * \}A}# 00\);_(* * \}A} 00\);_(*ef * \}A} 00\);_(*L * \}A} 00\);_(*23 * \}A}$ 00\);_(* * \}A} 00\);_(*ef * \}A} 00\);_(*L * \}A} 00\);_(*23 * \}A}% 00\);_(* * \}A} 00\);_(*ef * \}A} 00\);_(*L * \}A} 00\);_(*23 * \}A}& 00\);_(* * \}A} 00\);_(*ef * \}A} 00\);_(*L * \}A}  00\);_(*23 * \}A}' 00\);_(* * \}A} 00\);_(*ef * \}A} 00\);_(*L * \}A}! 00\);_(*23 * \}-}> 00\);_(*}-}? 00\);_(*}(}@ 00\);_(*}-}A 00\);_(*}-}- 00\);_(*}-}. 00\);_(*}-}: 00\);_(*}-}; 00\);_(*}-}6 00\);_(* 20% - Accent1M 20% - Accent1 ef % 20% - Accent2M" 20% - Accent2 ef % 20% - Accent3M& 20% - Accent3 ef % 20% - Accent4M* 20% - Accent4 ef % 20% - Accent5M. 20% - Accent5 ef % 20% - Accent6M2 20% - Accent6  ef % 40% - Accent1M 40% - Accent1 L % 40% - Accent2M# 40% - Accent2 L˭ % 40% - Accent3M' 40% - Accent3 L % 40% - Accent4M+ 40% - Accent4 L % 40% - Accent5M/ 40% - Accent5 L % 40% - Accent6M3 40% - Accent6  L % 60% - Accent1M 60% - Accent1 23 % 60% - Accent2M$ 60% - Accent2 23 % 60% - Accent3M( 60% - Accent3 23 % 60% - Accent4M, 60% - Accent4 23f % 60% - Accent5M0 60% - Accent5 23 %! 60% - Accent6M4 60% - Accent6  23Ў % "Accent1AAccent1 Dr % #Accent2A!Accent2 }1 % $Accent3A%Accent3  % %Accent4A)Accent4  % &Accent5A-Accent5 [ % 'Accent6A1Accent6  pG %( Berekening Berekening  }% ) Controlecel Controlecel  %????????? ???*Gekoppelde celQGekoppelde cel }% +Goed;Goed  a% ,InvoerwInvoer ̙ ??v% - Komma.( Komma [0] /Kop 1?Kop 1 DTj%Dr 0Kop 2?Kop 2 DTj%? 1Kop 3?Kop 3 DTj%23 2Kop 41Kop 4 DTj% 3NeutraalCNeutraal  W% 4Notitieh Notitie   5OngeldigCOngeldig  %6$Procent9 Standaard % 7Titel1Titel DTj% 8TotaalOTotaal %DrDr 9UitvoeryUitvoer  ???%????????? ???:"Valuta;* Valuta [0]<Verklarende tekstI5Verklarende tekst %=WaarschuwingstekstK Waarschuwingstekst %XTableStyleMedium2PivotStyleLight16`_ SearchResults5fNf8@ XYXbQX]%9cp@]Lk@-X n%X]tsaU^PNG  IHDRj?/sRGB pHYs,K,K=@IDATx$WusygsԮ$VZe e0`lq|66`HB94;3;y{:k:Mb~}{}|>vf1,K/DF\&GxNq0-&ݾ!wӼw}Ƕkݦtm6\yjXTTgdsTf>?5:3ŃL,t.fr$:-AM&jkrv8&Qcׄ]nAҙ9_Qϳ疦}X"̶%m\,uyqU#M@l\VCz;M +L p(c?<6D6-`5_qzajtYv:fnQܔ+KF pK p‰㓁zN=D<ۖ(:4i:0yݶC;mp s1 p&J|#|t[2kk-7;5!7o9e3XJ^W{yD'=yg1Lgyߺ!nx͖eMFWaWvYh/?;1升SUyзmq]WW$Ecz~.&]$ ul벘Ent&әs`T0ʮ*UB"l>;ؽeOfRJ64pLjݰڶwS^ '/̮7S ɨj<˰'"|*?:F3YAԼ1ܥ`R"]|$1G ~(j *L{"㧗‰*+ѨnK/ܳc年 W(I~ ?< j~>ɽ<c#;SG<&+8ld/LVL‘\ljמFizN,}W -Գ]iqbplf\OP"OWVIǾԙ4BhC̝ 6̵_N+7K}ũlfD=-D6t|:g'g|zYGy[<{z(u[" K:Nt榶,pgb]fzt6heDgdKiȪE3ҿZpܑ +BIğ?maRFMCNs4mrYk3h*"\(/=} \ ⡗~ #ZO!K? p*a Ntv[al䣥.(āsmu:mۭNӖvˀb^WjOdM#LNo@ZR^+ XN!h< '|7L\ F+`]8ء\l*sG8vU}srel( $2Dm `]"%fBS ?8ph@[љ͝z6ʇ12ݝݝk:EV^!Lg22ew||+Rh cSot[zbkK`tm  pu{9vuV؃oӁLf7ur9 ٢l92|8 ^ZFæN\?ѕPuz0bs:c秔&7,2d$϶rYÏ E_lf1rn:xa}?VknAg0ۛA5#^an񆭝0U{¦b,Mg`mQYX6l;iprYWfQ~=alsuw;}UかtȦy=*zcU20qTOe`MAP m%ҙyOZz޸K`s9Xtm ~݀pc[lpvB(Nr̥E7JOυ_>jmYˇ\.I3/*V흐fHi\l"p`Pكq/ |Q Ʌ)_.3΁>]lQo2~fO[:P i?.fst$Smil8F ẼH止B[&NoE7]$梩t^&hgG۹ O- w_3\WL ]]&jwoW㮻KYZ;I6j jwYym[`u0ek0*Ls6, s>:P{).L89Jt!(56.L[z7CW,n䊓#f XNW7 `߽2lU 3 wkl81LrCρ%D q-L13 $ٖW9,0]YKuY޹@h'ɷe[az/ qm6 zl&/XJR 2ƛL6Iy#'=bt$9$qί1 S+_q 뺡C*媅hǝ'"(rź~tyҊ.YL,gGȀ!nGe>Ɠ |fx&K]X .D$g@8Vmi#H j!E s [t{< P2eR p$0f`œog.Y0ʹ+p*ˤǒ(T#BZٵlhߥm]q $F_>tx_P_oEe}Δ^*>oK?,Jût.s64s{2T*`0sER }@9lj4%M5df#SL@Io*Z4 ҖgYGG`08E"&@0I,{?}e?B0kFڷ9hgL8nw~!|b.G02isCRAn{ͨX&ɿꉎEvpޫz޺ff:&2Kѥ$VYdkcIUXHFX8]#p` kx ' :3jӯꚓp29KsHt [cW6Me$.þ<|\lP;ւEAtR33sKߙ i F{ȶv%Q1ϲU У`"Kŗ"`6,. \뚣 Kѩcj4JbNa5`n6Wu m`Maj¿^{z@iCw8o>42~)A:ff=zZvQNgCɲ+UϏ2/̅{m7)Qtv6{#q}$QKEnP[B;;,P2z+]VDɸi3Kzf" 'oX\25BC,V5h6{m2"6~xZ>tR }I> tUmG;/.wm|[3K\5aq]J>VݻoLGP(#,--ɫ ;]z+cOh31T66% b{K;>lHDO:/_:tlL-ɣ4EO䞛 oo+piZ <ci c@s=Wτx8{v찘LG^4\®MGV$b{@U2=~q3W/!|̐o~33n(?bwwvyÇWAIz׻ŗ&WCy]ؐ$0Y/}d^х7 GϫWup\o-Bֺ&ਖ਼Cn[7vOY"4XMDQ+|[bpTF?X~y;f={_׾5k,V6% Cy~ggϞ=ozӛwlڴwD!]Los+}1gA1= S|U.G& %#K?yąW.`bt4ԾgP,H+ä RQa)KyV*NgatiHίʯo -®_W/6 __+VDmi 5?ß .YBKY\\7!5X1z$я~T.YI!=numY 7CC-%%?K߹bʌBQ|nO&C)ߝTZeRb,-}RM o>h4JHݖN &taDT3( ЃJkk$£( ^X\d_&3^׿ux-r 7{Ɔlј+o2{U9G?Av-@WaC  Z"{B޾/ckdKJiP\6yRD=SljƽpۻlFڑ*o~nJ4 ͉ ;F]tx磁:V)2pQzbJ*A ?~Ϗ;&i3- w]ފ$ b׾2x+XgggaQTro)}]Z(8W_}U,e2<3 e7z{yO Qbڻ4A饗AlXɓ'i4=܃6R m[}g4L6i=)BY **f<k_lnqos('KyR ,BPy?!eBmR)kӏԩ4%Nʦ?22ImJP;򩾾>ĴR^PNT9R`5ya47??naaA{ENi5rysGAs %!R޽{鲛orRdh vfk͇R6)fDoPGvP*#۷o()-Vٹs'-eKNz>G#f[R9q]wu`kI,9X$>9._zޱωZ /\z_Ga^Aw?9VwErRٚJ*ߊ(!UJ^!-R*00/_Fꓟ$/qVZ9<- j#EO!Ġ6wB%M]wEu~G{r3Lf)2%}ӡ}@RZ*덻9k+*y M=vbs~CPZytl.jV#(PeQK"h[@/8}IzPB%X`U&~~`EZ P5^QTi_%ٞ]w t.j؊yG~ĸf&;t_f3P|Pq Ke=PEɪYf*-՘W =4`:uwr-\Xa&!J4De}kPgKSaTկj+6oܴ=wlaop{_HK4@00݊r§ J__M|zˀ]b`L$P%y_]$dSά Z\qu###*ZxVR J/Q4VCg~gů<0Ƿ3gΨI# M%MW E۞^wܲ.A*)bjt9kDKļXvs{Gz#D7FP\Ag {Ɗ`xxX}KP.p\L#+BH կXBQ@P7$@(c?-&um=B-JJkwDb˶ӊVĕXa pCMJq9wPgsʴhfQE@CzyOoozA~YB\UKbIXZW|[md{w5ڂrr{ruًXƎo]/W,^pqFKã&U(jPE]I:($EbA$AU*L>__P1CIBW'CɈLWfDBW ^`#XT>JA) Q%]aFr[N;[7Z{b6$r|e׮],vwt٦B}`hQJrm&㢤=pTj.'fd},/5&abaa@ɳ4< w)/{9b,OY[97\ #{')&6!)Ɏ)-Šg2~r>Jsgirm1h t%8kSnmrT+L*c{C 7:5 B #`#E "Po4ƄR|@S+hv¶[H_zHo(* mrq ̙]8C$PZ]iLy R?Ҋc#)~H!Ec*AqԤ,CCChX>V C~c14L"vA\a(VfAWNɣ|12Y+B§A8:t ,C4Fjp5VT[2'I*y-gR^-~n~`k. # kJU7*M$(JA(oTR94@Bn&)=@pX4=}MsśZʛ/,k}{\iK֯??FS_Obя~g T*Jk#Ѥp~Fe˿OT"%̛="gdDo8] #(pg&P,ՔT̒|o{XSh}VRXqg ށ{a55n dwW %ekぴ[XŔnGL|[Ҧ,YEM,\q/˩53 Q$0r\Ld7\v9m(* _;]V|E]k/lO>"fQl<2zihuMw 9P,P,Uqkmp(#&Sr%>`a*$GZPEl$EV # %䰶M(w֭ D2(Ǫ8l`slM/Y%tXX8zd*0Q4}cԀm{T.AdhmT-oy JvPU,@TfP#0ǚP4*z2vϵZJ/U_ pS4j eWGbtaәK8rəslo贗U4  MgRU1y@}~(#B֘p9 QiqVjJQ*WX13\rY}Qz-?:Q>GߡEe9-NFT\N??TҀ64m}2†,J%JW^8V,w2(& Mw +ޖ.`Ypj Ȳb,F4lkXTv`jI(xH E X,Ft yW. cri qȭhQ3 *Uz~gE3@ øyd:Vn.vNX pYC=]*R\&bxDYӑ,*dCɩ!-eimS)PBgԓs(xxfi{|^٧St\ro&rH7vVEƚ $p9AY\LpR<|-֐ Dҷ a€bn UnO#MS.f8,p >ʵI(é?`RJL,υNN_:yb,QoRLD5|0tR!yJYEϬ(XUU 0!CQߤPF]tRLmhѤ;ۋƎhf#)D-M9bI8655l87R-*DO}SXdgoWx .[4DlRutѣ"ƨ\^lؖI.咩!Z N2bpR:I~@ۣ6lxh^[+-NUMc Ũ/ĥpq1T<]i4?=e+&*P`&*| rroݺClH'ʡ LVTU_> }pWt_mޫAIdvB\Zetv>֜4"l~a1|rܷ%eN&:CMl " y//W"Ew$ bny0C FD!dyE 4qGi/ ,ͅ]IPiJ6W4CXNK HXB0p|HX 4 bۅT9(yYQF]n\\!#g|+BY(M) Bx0<X`f&Hn gGr|I%e)l D\ +-aL.zz+V]6QU.b<#HCH-k;> At:'Y-ʝ:E*?+$ù˨_Uf 7PqNu| @QWmV1Gl" Wdn| SG`UOkhX|ZtMwُ-|n{fa\K75w͂~1}햞v<^/C&J2U"*/O gy\c~5wRg59kƙ QBz*n.wd4*;:].e㲙rW. ӢAu#awqLiKc` \cibOx$g_5r׫h!)gO/F{!zi>̡R"Ea ➵Br[HZ==;ݣ=,jwĉE_YB c5N)ٸX!F>o ;Ephi/}[-Փ(,Xɹ[>R <鲽@n0g`*]:#q|]YG,>'6q|&ҭSPCُW? j __`ڻQ njL܆*v ޚo[Q*½7\{GT/ξ쉝D#,>*VA$. _L0auYa[kZ4Ӭ 72Un5PVn4nݺ6C`hb1CK4T'o` "|')6L- Q)Hj2Tʑ;򟰞厄p.aĮu,#u\7v疌p^3ZxO]f#xiɛ솝6k: 1P i PK%@YU|%.R݇( SKQ *7b4 [ʁk!o)SޯŒ#F9`,t~`r.&m+aoqYh"}b_&Cv_ gnBҡIt\{\. WRs {Nqz{:זD˕6:P5 !,]Ljfa*&=}~tp#k;03Wj 9 $M}A[nO[|Qj,JL+%h쳛&Ctg)c8~J}b01c%7乾`L/opGERa@p!Tsp>LNm dcB"#RrgKT2FU\n1,:얎cK \WNrwEl\=1셗 ]\۷+/Fj9-* l,TKXiͪ%{[]6c5)8jǦlLݖgWn[ jxr=}@%B*``Yu6]~ kwqRŕr[|ݨ(Oɦs|f™`L_qvc϶84d7b9Va(x.%z>41UxCPb.<?9"E_uDխմ[q erO]T*8Ma2i닞G9ҨUG/UTE"8_$t9a-*dd ewL7:ee@oO.haMĢ:=vCȅP$Z+`j{>`',SqTU8F!+UXdGvJܫJ_ܘ(sb.in&afcT`΃s+7aZ[Qp{\T@Ho %|`МîZVX#pڠL䌀Zd_A%ྒྷTe9ǧhB^F{Z vb>P^GXS| r'o_U%`)#7Gbu?v0Uy%qCF}]V~ Hzr&ơ {4Nx1µPa #4+ʌ=d0TiU;p <{z6b/ IaRC[ y熴oeS= ^{pG1US#pYp_:tb:%cU5<1\-8y-rьYl gɎ 8%\2#âML)A#CKyi9/Zh Wv)]GGiRE`xh"/ˈf)%0CH.#%X@:MLͦ|?Mda4F./.P6e^*. 88O~RERo&9h3 ZOOtMj3/G>Q .x%Nᰚ>ʥH%HT6O6\bv>19#*M}΋70KUWc W'2Uզ9/NQ|B+"XC/hrkL(?a',2",7%~"]1WMbjKa1S* Ho S4Kz|E|8/bsl~TvE#pʖͥ=h>moy&/5_5p}KcKcd>"2fKyРQL_4jw[Kٙ~H/!"r =hQDJ2~JI _ts5FJgrek  I4&X6k<ý{Km6PZl؅@ںKP<` XT/= yf=yإW@p"٥0S[o@JYO^3iW8ytW`o8O/M*!*Ji*Plt< J< `<{nرuFUbLÚ ,(A$KlEಉ0ed8|,2%=IM ['L<'WFq*Yd< jb.D4CZxA0=){*w!(Vm6_">6ʶL]J1FKu[NRKuvd.\NʛT.\p9xf:X Jk\ YbMSWDJ6bIH=4l\FQ{p/w`}OQ|3~Tl(] kHQ-hզ(_ER|g+*={7l 99<8?\^ Ij})K$KDp.W@h ^^Q Chh0xP/Ȗ$SLSTv2rUu:6scIoeԊ=ur敳t,@+p!fCx#%Ro(k\F^[ 2 *`W#îzc.m:hmͼ5,p Jz+r"xRշRgfK7/h2^U4YƹR8^NM7RXyՠAsrؕ%MGEf*}f R^ H*əKR&"Df&MY j-}fK.9v .iZCT'/疷glqDOpknG6GOφ]j&#HėzT XLh9Rxi\PnQ.9G LDBˏhߍJ<ޱr@* 9nX:vf.!^Q)2Xl,%X>ǃw|b.~nhKЌP?X2K܂`hB{܆b1x-#UC7##fի𠩛^JԶ<՞kej1/>a/ M7-hS C{EǼ:eXd:wl·s(\R\I>Xf%/z ufLP8MjRsD |f\^wj/bNp%Ds9пt*J酥L$D@iBZ YŬjec4Ax. 2ggBRGmh q&&S &=|8"0 ;HUHzZ ;7t6ҸmĸH2gbKl (0,Cϗ2{5r:*ws Z54,V^y|!\Pͬŏ^{`pU.C=$D&j"H(.6_4d( `T^LF,Wo&;|jW'+T_b{ܳIDATy1vVZ.lMk\ 5G&؋֗5(K!н1W4)/h,C f<"Ae+;kA|ECiz#q_ Kkx/?z/bX&qS˪I9 ÝւytI%3N 6F 9iB|$6@JC@ Km. `M&-zUO$-?zy|t]Wlx4j6ˁi Xkr,B07,tj_?j8U8"E8Û>.Mp- $^g(-P0ܫmnm7wX\aF|(C~t7or̪TN=FR!lԸr jq%w:)P:*W\j>"2_uS0mCZLfWd${x5DqumEj+#ct hv @OB(oy%ڒC|QʢS R[O]}VCuhg=RzMrZM[z]Ϟ[*055-PjX6l{;6w aaZ)+-M>P$Ow_F׶䫤ېwu$THl6?ƒ W%Vp\P- .D읛;WvXu=_{B(6cd4lR|r`ﲪVpMd/{c#+eZ% sP|;ٙUU.gyq&`d~clɓH0D[`=Dno {pĴ.$}:U \nH}0'uOĝ/}l*0IvSVd+jɹ^鍥NA+XܴoH_GU| λ;}S,[t#iJ^0g{7ov[m2k'"OM/ч^ 5Ѻ\VlIJGp)sv΅MUVќg''{⩫7UQlzd<zNL?Jo8|նv>tp͗լQ['pwE+5H'yr6|qce/}7:ubڟ wT6Msݎj \q޼w7iV54W"h_r h'/yl&9 =^نAZb~#~ķ;;0i2(~> bwS~you}qp|/-Ftuۆ\و4>a<œ'ѱOLMy\P6ˍoa%mquCXpް^S?Y6V*4Ë!ǎ[h7,[T*N$رѹgO\xR4)0֐Cr}[{knU\wģ'ҙgOpֺ)^P;n]O(VZ%p ŏNE0S,鑹<ޫ )4L?~>}6Ӱ˼elf#4bq6Q0ƲsAKffīۇ(FW^isCӾ1o$]ە TVgk"'!2Y &tFVg7uX6@ fqˬ6Pd)\>@\=R86:4UMdU!+Lұ*:US\]{|5pn54#XțMs/A(a#T$}Ȥzm&}h.t:܂oIm7|_4̤lDUZA@}WGz;RA]hye `nACمt*81;w~:cAD|덻~7u5ε 7uw|'Cr.ufe_5LG΅٥x,v>ZW/ G梩\:-ڢ\yñ_:7pח&gfp&s]}V*N0[o߻6 ';Z!kAgr ǠLD}77]À v3ONhMi}p =ͤӁy\T,FouorXсFWlߔ'#pLS<zmk2h`λ85r)v`o~큑wڃ7)v!.B~z:HRP4KRs[`w]˗h|-<%/iL!(h}Cqu;ۛh pőBɵBp\^k2&Vg7]u"S(Ū&_H$RnWunۡCoc5;Lgޚ\&#NO6r kLW"|H`_H7rU",ÝnsWԣyi.pŖ%ȩ\1|CTЋlqX[y"%ch Y }Fg q~ס=npos%q%+й78.-1PÑoނZIebH`$ a,*ksZLwoM p3+\Tv;;\@ P" Io@ ^rMIŒ_0R(1,nㄉ6z权]k`־.\@|ޟX '=P2Pjvr ܳjjgWu[뽸UFs,wwXߕA҂{2i0[ tai2fR[=kC6xUmEMX lJ_\[5=փN ZbZtk9m֞eӵXu 7U²rÏa`.zAZ3Qd_iƑ nYb${xSk̸6; eZ- \fg{ N7`5vS&Qp* 87 { BI>6^^Xp/&ŁZ 7 :- ]HoL.D0tۦV0`ٽERhRkl}2^;Ҿm.oo? \n~ݶΝ. [zݐU\ҢlPy orkkvuoL0:ݠbáHݍ  H+Q2ӫLzh$;e5䊻+]+<l| {.eD߮XLA鎑{E p `"s}v61ͬ|b8L-Z65E?h@\"=EќYEfQE볙8yMmʹ6( p$p*\Rτ3teTBP ]F}Eˎ3Ɉ&P^nAg,L0 x:ӂ3i h4 CJf]15 Cv5u ^+W{y,ʆ2^GRl4\<Vv]F=<>͛\!y \&]}W<.*tf> %Ghj)T:̆qۺ68L}W* IENDB`S AA@A@  TitleAcronymStatus Conditions Interventions LocationsURL<18F-PSMA PET/CT for Visualization of Glioblastoma MultiformePSMA-GBMUnknown statusGlioblastoma MultiformeOther: 18F-PSMA-1007 PET tracer+https://ClinicalTrials.gov/show/NCT04588454[PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas Recruiting(Sarcoma,Soft Tissue|Urothelial Carcinoma,Diagnostic Test: [18F]-JK-PSMA-7 PET/CT scan+https://ClinicalTrials.gov/show/NCT05522257'EBRT + Lu-PSMA for N1M0 Prostate Cancer PROQURE-1Prostatic Neoplasm$Drug: 177Lu-PSMA-617|Radiation: EBRT+https://ClinicalTrials.gov/show/NCT05162573jEvaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid CancerMIMETICkMedullary Thyroid Cancer|Medullary Thyroid Carcinoma|Thyroid Carcinoma, Medullary|Thyroid Cancer, MedullaryDrug: 18F-PSMA-1007+https://ClinicalTrials.gov/show/NCT05534594NPSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide PET-MaN-enzaNot yet recruitingProstate Cancer0Diagnostic Test: PSMA-PET/CT response evaluation+https://ClinicalTrials.gov/show/NCT05539300PLutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer PatientsLUPSAFSalivary Gland Cancer|Salivary Duct Carcinoma|Adenoid Cystic CarcinomaDrug: Lutetium-177-PSMA-I&T+https://ClinicalTrials.gov/show/NCT04291300>PSMA-PET Imaging Before and After ADT in Advanced SDC PatientsADT-SCAN-Salivary Gland Cancer|Salivary Duct Carcinoma?Diagnostic Test: 68Ga-PSMA-PET/CT|Diagnostic Test: 18FDG-PET/CT+https://ClinicalTrials.gov/show/NCT04214353%PSMA-PET Imaging for Advanced ACC/SDC CompletedFSalivary Gland Cancer|Adenoid Cystic Carcinoma|Salivary Duct Carcinoma!Diagnostic Test: PSMA-PET/CT scan+https://ClinicalTrials.gov/show/NCT03319641EF18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer PROPER-ABXProstate Cancer RecurrentNDiagnostic Test: F18-fluciclovine PET/CT|Diagnostic Test: F18-PSMA-1007 PET/CT+https://ClinicalTrials.gov/show/NCT04239742;18F-PSMA-1007 PET Imaging to Detect Primary Prostate CancerPICture%Diagnostic Test: 18F-PSMA-1007 PET/CT+https://ClinicalTrials.gov/show/NCT04487847>Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate CancerProstate NeoplasmDrug: Lu-177 PSMA-617+https://ClinicalTrials.gov/show/NCT03828838xDutch National Randomized Study: PSMA-PET/CT as a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients PSMA-SELECT@Prostate Cancer Metastatic|Prostate Cancer|Lymph Node Metastases#Device: PSMA-PET/CT|Other: Nomogram+https://ClinicalTrials.gov/show/NCT05000827KAccuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRIMAGNIFY%Prostate Cancer|Lymph Node Metastases,Diagnostic Test: Ferumoxtran-10 enhanced MRI?PSMA Response in Metastasized Hormone Sensitive Prostate CancerPET-MaNDiagnostic Test: PSMA-PET/CT+https://ClinicalTrials.gov/show/NCT05161728KLutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate CancerBullseyeDrug: 177Lu-PSMA-617+https://ClinicalTrials.gov/show/NCT044430622Dose-Effect Relation of Salivary Gland IrradiationHNSCCDevice: PSMA PET/CT-scan+https://ClinicalTrials.gov/show/NCT03367780FTechnetium Based Radioguided Surgery for Prostate Cancer (TRACE) StudyTRACE#Procedure: PSMA-radioguided surgery+https://ClinicalTrials.gov/show/NCT03857113iStudy Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentSPLASH/Metastatic Castration-Resistant Prostate Cancer;Drug: [Lu-177]-PNT2002|Drug: Abiraterone|Drug: Enzalutamide+https://ClinicalTrials.gov/show/NCT04647526QStudy of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.POTENTIA(Advanced and/or Metastatic Solid Tumours Drug: CB307+https://ClinicalTrials.gov/show/NCT04839991BPSMA-PET Guided Hypofractionated Salvage Prostate Bed RadiotherapyPERYTON!Prostate Cancer|Cancer Recurrence?Radiation: Conventional sEBRT|Radiation: Hypofractionated sEBRT+https://ClinicalTrials.gov/show/NCT04642027An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC PSMAdditionProstatic Neoplasms<Drug: 177Lu-PSMA-617|Drug: 68Ga-PSMA-11|Drug: ARDT|Drug: ADT+https://ClinicalTrials.gov/show/NCT04720157HStudy of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate CancerVISIONActive, not recruitingADrug: 177Lu-PSMA-617|Other: Best supportive/best standard of care+https://ClinicalTrials.gov/show/NCT03511664177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerPSMAforeNDrug: 177Lu-PSMA-617|Drug: 68Ga-PSMA-11|Drug: ARDT|Other: Best supportive care+https://ClinicalTrials.gov/show/NCT04689828NRadio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer PatientsDETECT@Procedure: Radio guided surgery (RGS) using Indium-labelled PSMA+https://ClinicalTrials.gov/show/NCT04300673WEfficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer)Prostate Cancer|Prostate Cancer RecurrentDrug: [18F]PSMA-1007+https://ClinicalTrials.gov/show/NCT04742361YSafety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC?Metastatic Castration-resistant Prostate Cancer|Prostate CancerZDrug: acapatamab|Drug: Pembrolizumab|Drug: Etanercept|Drug: Cytochrome P450 (CYP) Cocktail+https://ClinicalTrials.gov/show/NCT03792841Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT) Drug: rhPSMA-7.3 (18F) Injection+https://ClinicalTrials.gov/show/NCT04186845Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)+https://ClinicalTrials.gov/show/NCT04186819\Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapyADOPT)Radiation: Radiotherapy|Drug: Leuprorelin+https://ClinicalTrials.gov/show/NCT04302454LUMCUMCG Radboudumc(Canisius Wilhelmina Ziekenhuis, NijmegenNKI-AvLLMeander MC|Canisius-Wilhelmina Ziekenhuis, Nijmegen|St Antonius Utrecht|UMCU$AmsterdamUMC|NKI-AvL|UMCG|RadboudumcNKI-AVL|UMCG|UMCUCSt. Antonius Nieuwegein|Radboudumc|Erasmus UMC|groot internationaal@NKI-AvL|Amsterdam UMC|UMCG|Erasmus UMC|UMCU|groot internationaal4Radboudumc|Canisius Wilhelimina Ziekenhuis, NijmegenENKI-AvL|St. Antonius Nieuwegein|Radboudumc|UMCU| groot internationaalRadboudUMC | internationaalErasmus MC|groot internationaalNovartisFriesland|Arnhem|Radboudumc|Maastricht|Catharina Hospital, Eindhoven|Amsterdam UMC | Deventer| Zwolle|Haga Hospital, Den Haag|LUMC|Erasmus MC|UMCG|Verbeeten Institute, Tilburg Start DateCompletion Date SPOTLIGHT LIGHTHOUSEOverzicht PSMA clinical trialsRadiotherapy Institute Friesland|Radiotherapiegroep, Arnhem|Radboudumc|Maastro Clinic, Maastricht|Catharina-Hospital, Eindhoven|Verbeeten Institute, Tilburg|Amsterdam UMC|Deventer|Haga Hospital, Den Haag, |LUMC|Erasmus MC|UMCGPI/contact personTRadboudumc | Catharina Ziekenhuis Eindhoven |Canisius Wilhelmina Ziekenhuis Nijmegen:CWZ, Nijmegen |Maxima MC, Veldhoven | groot internationaal9CWZ, Nijmegen|Maxima MC, Veldhoven | groot internationaalLioe-Fee De Geus-Oei Wouter VogelAdrienne BrouwersRoderick van den Bergh.UMCU/Antonius Ziekenhuis, Utrecht, NetherlandsJames NagarajahCarla ML van HerpenJean-Paul van BastenPim van LeeuwenPOINT biopharmaCrescendo Biologics Ltd.Shafak Al-Uwini AAA/NovartisMichiel Sedelaar"ABX advanced biochemical compoundsAmgenBlue Earth Diagnostics/https://clinicaltrials.gov/ct2/show/NCT03223064 Fred Witjes 'ԍ^f<  D 0o;xllpħNccc[  PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VpE(|oϟ^8p40}a3!_͢"bY|;\wdhgpMl1qMO,O%qF1d=4ܛ{Щkw +qlآyLAQc,=`츻'Xq= CK 8C' ]A^f.j+6&nS }L0CS">}$CތM\GHt):#,Iq"%|#LdMZ!G(Q30 QאLct_,@\MJEoܑ{Yۛ1.ᑥ;89 ǘ34{t+!.vdתk%rd{8`+gU!f;RzDxH`zqHWz=ջԵp[3E%+ۀ6MQk` ܂DUm6uڍ퇶H Fּga;c0۱%YWuVI€ khc$˚u3L5>լzofU,Ìq3d'+f)liGzʣ|G>cBiO(G/Q>`G` pmWHW[m68hÔ;RT;k` $ mPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]  ZO 9  dMbP?_*+%,&ffffff?'ffffff?(?)?M  dXX" dXX333333?333333?&<3cAU } *} * }  } } L>} } >} ,}   1@ @ @ @ @   @ @ @ @ @ @  @   @ @  X@     ,@ @  X@  @  AAAAAAAA    >    >    ?@@ ? >    >    @@@? >    >    @@@@ ? >    >    @@@ ? >    >    @@@ ? >    >  !  @@@@ ?# >"  $ % >  &  @@@@ ?( >'  ) * >  +  @  @@@ ? >, - . / > 0 @ "@@@ ?2 >1  3 4 > 5  $@@@ ?7 >6   8 > 9  &@@@ ? >: - ; < > =  (@@@ ?? >>  @ A > B ~ *@~ @ ?D >C  E F >    ,@@@ ?H >G   I >  J  @.@@@ ?L >K   M >  N  0@@@? >O - P Q >  R  1@@@ ?T >S   U >  V  2@@@ ?X >W  Y Z >  [  3@@@ ?] >\  ^ _ >  `  4@@@ ?b >a  c d >  e  5@@@ ?g >f  h i >  j  6@@@ ?l >k m  n >  o  7@@@ ?q >p m h r >  s  8@@@ ?u >t m E v >  w  9@@@? >x  y z >  {  :@@@? >| m } ~ >    ;@@@ ? > -   >    <@@@ ? > -   >    =@@@ ? >    >    BX&fN(    N^X  QQ?@I @]4@ *KjHD㪰";5 '<([Opmerkingenthread] U kunt deze opmerkingenthread lezen in uw versie van Excel. Eventuele wijzigingen aan de thread gaan echter verloren als het bestand wordt geopend in een nieuwere versie van Excel. Meer informatie: https://go.microsoft.com/fwlink/?linkid=870924 Opmerking: Tracer study?<'~  DA??Picture 1 ]&`5 )tc={DA97B571-97ED-40B1-8F25-546E3E0A780C}>@d{DzD9d ggD Oh+'0@H` 'Priv, BastiaanMicrosoft Office-gebruikerMicrosoft Macintosh Excel@/0@v$Q ՜.+,0HP X`hp x ' SearchResults  Werkbladen  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefgijklmnoqrstuvwRoot Entry FWorkbookbSummaryInformation(hDocumentSummaryInformation8p